Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: measurement of inflammatory markers for Asthma Bronchial
A low-intervention, prospective, experimental study will be conducted with the overall aim of assessing the inflammatory, functional and clinical differences between patients with asthma and those with asthma and hypertension, in order to improve our understanding of asthma and its comorbidities
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 74 people at Tradate. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Interventions: measurement of inflammatory markers
Primary outcome (registry wording): Interleukin 4
Who it is for (from inclusion criteria)
Ages 18 Years to 85 Years
Age ≥18 and ≤85 years;
Diagnosis of moderate/severe asthma according to current Global Initiative for Asthma (GINA) guidelines
Diagnosis of moderate/severe asthma according to current GINA guidelines and primary arterial hypertension according to current European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines
Patients able to collaborate in the required procedures;
Who the registry excludes
History of asthma exacerbation requiring changing of pharmacological treatment in the previous month
Active smoking status or ex-smoker with Pack/Year major than 10;
This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.
Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07903805?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07903805?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.